BioVie Inc. (BIVI) NASDAQ
1.70
+0.21(+14.09%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
BioVie Inc.
Address
680 West Nye Lane
Carson City, NV 89703
United States of America (the)
Phone
775 888 3162
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
September 18, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Cuong Viet Do | President, Chief Executive Officer & Director | 710,700 | 1966 |
| Joanne Wendy Kim | Chief Financial Officer, Treasurer & Corporate Secretary | 400,000 | 1956 |
| Joseph Palumbo | Executive Vice President of R&D and Chief Medical Officer | 644,000 | 1961 |
| Christopher L. Reading | Senior Vice President of Alzheimer's Disease Program | 0 | 1948 |
| Penelope Markham | Senior Vice President of Liver Disease Program | 0 | 1966 |
| Clarence N. Ahlem | Senior Vice President of Operations | 0 | 1956 |
| David Morse | Senior Vice President & Chief Regulatory Officer | 0 | N/A |
| Denise Smith | Senior Vice President of Manufacturing & Development | 0 | N/A |
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
